These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38057096)

  • 21. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
    Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
    Konkwo C; Perry RJ
    Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
    Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
    Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
    BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Imeglimin: features of the mechanism of action and potential benefits].
    Kuznetsov KO; Saetova AA; Mahmutova EI; Bobrik AG; Bobrik DV; Nagaev IR; Khamitova AD; Arapieva AM
    Probl Endokrinol (Mosk); 2022 Mar; 68(3):57-66. PubMed ID: 35841169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
    Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
    Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
    Theurey P; Vial G; Fontaine E; Monternier PA; Fouqueray P; Bolze S; Moller DE; Hallakou-Bozec S
    Physiol Rep; 2022 Mar; 10(5):e15151. PubMed ID: 35274817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
    Dubourg J; Perrimond-Dauchy S; Felices M; Bolze S; Voiriot P; Fouqueray P
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1393-1400. PubMed ID: 32556539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Imeglimin for Type 2 Diabetes in Patients Undergoing Dialysis.
    Mima A
    In Vivo; 2023; 37(3):1334-1338. PubMed ID: 37103109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Biology (Basel); 2023 May; 12(5):. PubMed ID: 37237539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
    Osonoi T; Shirabe S; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
    Front Pharmacol; 2023; 14():1205021. PubMed ID: 37351507
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ
    Nakanishi Y; Higuchi J; Honda N; Komura N
    Nihon Yakurigaku Zasshi; 2021; 156(6):370-381. PubMed ID: 34719572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus.
    Guo LX; Liu GE; Chen L; Wang HF; Guo J; Zheng XL; Duan BH; Wang DZ; Zhu W; Wang K; Tan WS; Chen Q; Li QZ; Yang J; Zhang Q; Xie PF; Lei MX
    Front Endocrinol (Lausanne); 2021; 12():712200. PubMed ID: 34659110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
    Ishibashi R; Hirayama K; Watanabe S; Okano K; Kuroda Y; Baba Y; Kanayama T; Ito C; Kasahara K; Aiba S; Iga R; Ohtani R; Inaba Y; Koshizaka M; Maezawa Y; Yokote K
    J Diabetes Investig; 2023 Dec; 14(12):1419-1422. PubMed ID: 37715448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans.
    Clémence C; Fouqueray P; Sébastien B
    Drug Metab Dispos; 2020 Dec; 48(12):1330-1346. PubMed ID: 33020063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.
    Chevalier C; Dubourg J; Bolze S; Fouqueray P
    Clin Pharmacokinet; 2021 Apr; 60(4):485-490. PubMed ID: 33169345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.
    Tomita Y; Hansson E; Mazuir F; Wellhagen GJ; Ooi QX; Mezzalana E; Kitamura A; Nemoto D; Bolze S
    Clin Transl Sci; 2022 Apr; 15(4):1014-1026. PubMed ID: 34962074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imeglimin in type 2 diabetes.
    Huston J; Schaffner H; Langley L; Skrable B; Ashchi A; Berner J; Gore A; Sheikh-Ali M; Sutton D; Goldfaden R
    Drugs Today (Barc); 2022 Sep; 58(9):437-449. PubMed ID: 36102904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation and Evaluation of Multilayered Tablets of Pioglitazone Hydrochloride and Metformin Hydrochloride.
    Chowdary YA; Raparla R; Madhuri M
    J Pharm (Cairo); 2014; 2014():848243. PubMed ID: 26556204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.